Liver Diseases pp 305-318 | Cite as

Cirrhotic Cardiomyopathy

  • Roxana Cristina Rimbas
  • Alexandra Maria Chitroceanu
  • Dragos Vinereanu


Liver cirrhosis (LC) is an important cause of mortality in adults. Access to liver transplant (LT) has improved significantly the prognosis of this disease. Cardiac dysfunction is considered the main cause of mortality after LT. However, the most updated pre-LT evaluation guideline provides only an algorithm for the evaluation of major cardiovascular diseases, without giving any clear recommendations for cirrhotic cardiomyopathy (CCM).

CCM is defined as a cardiac dysfunction that includes impaired cardiac contractility, with subclinical systolic and diastolic dysfunction, electromechanical abnormalities associated with augmented vascular function, in the absence of other known causes of cardiac disease. CCM contributes to various complications in cirrhosis, especially in the development of heart failure in relation to invasive procedures, surgical intervention, and LT. Its diagnosis is based mostly on conventional echocardiography, revealing mainly diastolic dysfunction. The roles of new methods, tissue Doppler imaging (TDI) and speckle tracking echocardiography (STE) in the diagnosis and prognosis of CCM remain controversial. These methods might be essential in early detection and better definition of cardiac dysfunction in presumed high preload conditions. However, they are not yet included in the CCM diagnosis algorithm. Furthermore, measurement of circulating levels of cardiac biomarkers could improve the diagnostic assessment. Current pharmacological treatment is nonspecific and liver transplantation is the only potential treatment with specific effect on CCM. The therapeutic options should follow the recommendations for the treatment of liver cirrhosis and heart failure.


Cirrhotic cardiomyopathy Diastolic dysfunction Systolic dysfunction Electrophysiological abnormalities Biomarkers 


  1. 1.
    Martin P, DiMartini A, Feng S, Brown R Jr, Fallon M. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology. 2014;59:1144–65.PubMedCrossRefGoogle Scholar
  2. 2.
    Mocarzel LOC, Rossi MM, Miliosse B de M, Lanzieri PG, Gismondi RA. Cirrhotic cardiomyopathy: a new clinical phenotype. Arq Bras Cardiol. 2017;108:564–8.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Zaky A, Bendjelid K. Appraising cardiac dysfunction in liver transplantation: an ongoing challenge. Liver Int. 2015;35:12–29.PubMedCrossRefGoogle Scholar
  4. 4.
    Møller S, Hove JD, Dixen U, Bendtsen F. New insights into cirrhotic cardiomyopathy. Int J Cardiol. 2013;167:1101–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Merli M, Calicchia A, Ruffa A, Pellicori P, Riggio O, Giusto M, et al. Cardiac dysfunction in cirrhosis is not associated with the severity of liver disease. Eur J Intern Med. 2013;24:172–6.PubMedCrossRefGoogle Scholar
  6. 6.
    Nazar A, Guevara M, Sitges M, Terra C, Solà E, Guigou C, Arroyo V, Ginès P. Left ventricular function assessed by echocardiography in cirrhosis: relationship to systemic hemodynamic and renal dysfunction. J Hepatol. 2013;58:51–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Sampaio F, Pimenta J, Bettencourt N, Fontes-Carvalho R, Silva AP, Valente J, et al. Systolic and diastolic dysfunction in cirrhosis: a tissue-Doppler and speckle tracking echocardiography study. Liver Int. 2013;33:1158–65.PubMedCrossRefGoogle Scholar
  8. 8.
    Sampaio F, Pimenta J, Bettencourt N, Fontes-Carvalho R, Silva AP, Valente J, et al. Systolic dysfunction and diastolic dysfunction do not influence medium-term prognosis in patients with cirrhosis. Eur J Intern Med. 2014;25:241–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Naqvi IH, Mahmood K, Naeem M, Vashwani AS, Ziaullah S. The heart matters when the liver shatters! Cirrhotic cardiomyopathy: frequency, comparison, and correlation with severity of disease. Gastroenterol Rev. 2016;11:247–56.CrossRefGoogle Scholar
  10. 10.
    Enache I, Oswald-Mammosser M, Woehl-Jaegle M-L, Habersetzer F, Di MP, Charloux A, Doutreleau S. Cirrhotic cardiomyopathy and hepatopulmonary syndrome: Prevalence and prognosis in a series of patients. Respir Med. 2013;107:1030–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Gassanov N, Caglayan E, Semmo N, Massenkeil G, Er F. Cirrhotic cardiomyopathy: a cardiologist’s perspective. World J Gastroenterol. 2014;20:15492–8.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Wiese S, Hove JD, Bendtsen F, Møller S. Cirrhotic cardiomyopathy: pathogenesis and clinical relevance. Nat Rev Gastroenterol Hepatol. 2014;11:177–86.PubMedCrossRefGoogle Scholar
  13. 13.
    Horvatits T, Drolz A, Rutter K, Roedl K, Kluge S, Fuhrmann V. Hepato-cardiac disorders. World J Hepatol. 2014;6:41–54.CrossRefGoogle Scholar
  14. 14.
    Møller S, Bernardi M. Interactions of the heart and the liver. Eur Heart J. 2013;34:2804–11.PubMedCrossRefGoogle Scholar
  15. 15.
    Mota VG, Markman Filho B. Echocardiography in chronic liver disease: systematic review. Arq Bras Cardiol. 2013;100:376–85.PubMedGoogle Scholar
  16. 16.
    Liu H, Jayakumar S, Traboulsi M, Lee SS. Cirrhotic cardiomyopathy: implications for liver transplantation. Liver Transpl. 2017;23:826–35.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Nagueh SF, Smiseth OA, Appleton CP, Benjamin F, Dokainish H, Edvardsen T, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29:277–314.CrossRefGoogle Scholar
  18. 18.
    Rimbaş RC, Baldea SM, Guerra RDGA, Visoiu SI, Rimbaş M, Pop CS, Vinereanu D. New definition criteria of myocardial dysfunction in patients with liver cirrhosis: a speckle tracking and tissue Doppler imaging study. Ultrasound Med Biol. 2018;44:562–74.PubMedCrossRefGoogle Scholar
  19. 19.
    Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28:1–39.PubMedCrossRefGoogle Scholar
  20. 20.
    Sampaio F, Lamata P, Bettencourt N, Alt SC, Ferreira N, Kowallick JT, et al. Assessment of cardiovascular physiology using dobutamine stress cardiovascular magnetic resonance reveals impaired contractile reserve in patients with cirrhotic cardiomyopathy. J Cardiovasc Magn Reson. 2015;17:61.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Altekin RE, Caglar B, Karakas MS, Ozel D, Deger N, Demir I. Evaluation of subclinical left ventricular systolic dysfunction using two-dimensional speckle-tracking echocardiography in patients with non-alcoholic cirrhosis. Hell J Cardiol. 2014;55:402–10.Google Scholar
  22. 22.
    Izzy M, Oh J, Watt KD. Cirrhotic cardiomyopathy after transplantation: neither the transient nor innocent bystander. Hepatology. 2018; Scholar
  23. 23.
    Chen Y, Chan AC, Chan SC, Chok SH, Sharr W, Fung J, Liu JH, et al. A detailed evaluation of cardiac function in cirrhotic patients and its alteration with or without liver transplantation. J Cardiol. 2016;67:140–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Naqvi IH, Mahmood K, Talib A, Rizvi NZ. Looking beyond liver! cirrhotic cardiomyopathy: pathophysiology, clinical presentation and management strategies. J Gastroenterol Liv Pancr Dis. 2017;2:1009.Google Scholar
  25. 25.
    Carvalheiro F, Rodrigues C, Adrego T, Viana J, Vieira H, Seco C, et al. Diastolic dysfunction in liver cirrhosis: prognostic predictor in liver transplantation? Transplant Proc. 2016;48:128–31.PubMedCrossRefGoogle Scholar
  26. 26.
    Ruiz-Del-Arbol L, Achecar L, Serradilla R, Rodriguez-Gandia MA, Rivero M, Garrido E, Natcher JJ. Diastolic dysfunction is a predictor of poor outcomes in patients with cirrhosis, portal hypertension and a normal creatinine. Hepatology. 2013;58:1732–41.PubMedCrossRefGoogle Scholar
  27. 27.
    Sampaio F, Pimenta J. Left ventricular function assessment in cirrhosis: current methods and future directions. World J Gastroenterol. 2016;22:112–25.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Oh JK, Kane GC. Diastolic stress echocardiography: the time has come for its integration into clinical practice. J Am Soc Echocardiogr. 2014;27:1060–3.PubMedCrossRefGoogle Scholar
  29. 29.
    Dahl EK, Møller S, Kjær A, Petersen CL, Bendtsen F, Krag A. Diastolic and autonomic dysfunction in early cirrhosis: a dobutamine stress study. Scand J Gastroenterol. 2014;49:362–72.PubMedCrossRefGoogle Scholar
  30. 30.
    Krag A, Bendtsen F, Dahl EK, Kjær A, Petersen CL, Møller S. Cardiac function in patients with early cirrhosis during maximal beta-adrenergic drive: a dobutamine stress study. PLoS One. 2014;9:e109179.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Barbosa M, Guardado J, Marinho C, Rosa B, Quelhas I, Lourenço A, et al. Cirrhotic cardiomyopathy: isn’t stress evaluation always required for the diagnosis? World J Hepatol. 2016;8:200–6.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Umphrey LG, Hurst RT, Eleid MF, Lee KS, Reuss CS, Hentz JG, et al. Preoperative dobutamine stress echocardiographic findings and subsequent short-term adverse cardiac events after orthotopic liver transplantation. Liver Transpl. 2008;14:886–92.PubMedCrossRefGoogle Scholar
  33. 33.
    Wiese S, Hove JD, Møller S. Cardiac imaging in patients with chronic liver disease. Clin Physiol Funct Imaging. 2017;37:347–56.PubMedCrossRefGoogle Scholar
  34. 34.
    Mozos I. Arrhythmia risk in liver cirrhosis. World J Hepatol. 2015;7:662–72.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Pall A, Czifra A, Vitális Z, Papp M, Paragh G, Szabó Z. Pathophysiological and clinical approach to cirrhotic cardiomyopathy. J Gastrointestin Liver Dis. 2014;23:301–10.PubMedGoogle Scholar
  36. 36.
    Kimer N, Goetze JP, Bendtsen F, Moller S. New vasoactive peptides in cirrhosis: organ extraction and relation to the vasodilatory state. Eur J Clin Investig. 2014;44:441–52.CrossRefGoogle Scholar
  37. 37.
    Chayanupatkul M, Liangpunsakul S. Cirrhotic cardiomyopathy: review of pathophysiology and treatment. Hepatol Int. 2014;8:308–15.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Ruiz-del-Árbol L, Serradilla R. Cirrhotic cardiomyopathy and circulatory function. World J Gastroenterol. 2015;21:11502–21.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Silvestre OM, Farias AQ, Ramos DS, Furtado MS, Rodrigues AC, Ximenes RO, et al. β-Blocker therapy for cirrhotic cardiomyopathy: a randomized-controlled trial. Eur J Gastroenterol Hepatol. 2018;30:930–7.PubMedCrossRefGoogle Scholar
  40. 40.
    Sonny A, Ibrahim A, Schuster A, Jaber WA, Cywinski JB. Impact and persistence of cirrhotic cardiomyopathy after liver transplantation. Clin Transpl. 2016;30:986–93.CrossRefGoogle Scholar

Further Reading

  1. Acosta F, De La Morena G, Villegas M, Sansano T, Reche M, Beltran R, Roques V, et al. Evaluation of cardiac function before and after liver transplantation. Transplant Proc. 1999;31:2369–70.PubMedCrossRefGoogle Scholar
  2. Alexopoulou A, Papatheodoridis G, Pouriki S, Chrysohoou C, Raftopoulos L, Stefanadis C, Pectasides D. Diastolic myocardial dysfunction does not affect survival in patients with cirrhosis. Transpl Int. 2012;25:1174–81.PubMedCrossRefGoogle Scholar
  3. Baik SK, Fouad TR, Lee SS. Cirrhotic cardiomyopathy. Orphanet J Rare Dis. 2007;2:15–27.PubMedPubMedCentralCrossRefGoogle Scholar
  4. Bolognesi M, Sacerdoti D, Piva A, Di Pascoli M, Zampieri F, Quarta S, Baik SK, Fouad TR, Lee SS. Carbon monoxide-mediated activation of large conductance calcium-activated potassium channels contributes to mesenteric vasodilatation in cirrhotic rats. J Pharmacol Exp Ther. 2007;321:187–94.PubMedCrossRefGoogle Scholar
  5. Bernardi M, Rubboli A, Trevisani F, Cancellieri C, Ligabue A, Baraldini M, et al. Reduced cardiovascular responsiveness to exercise-induced sympatho-adrenergic stimulation in patients with cirrhosis. J Hepatol. 1991;12:207–16.PubMedCrossRefGoogle Scholar
  6. Bernardi M, Calandra S, Colantoni A, Trevisani F, Raimondo ML, Sica G, Schepis F, Mandini M, Simoni P, Contin M, et al. Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology. 1998;27:28–34.PubMedCrossRefGoogle Scholar
  7. Bonz A, Laser M, Kullmer S, Kniesch S, Babin-Ebell J, Popp V, Ertl G, Wagner JA. Cannabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle. J Cardiovasc Pharmacol. 2003;41:657–64.PubMedCrossRefGoogle Scholar
  8. Cameli M, Lisi M, Mondillo S, Padeletti M, Ballo P, Tsioulpas C, Bernazzali S, Maccherini M. Left atrial longitudinal strain by speckle tracking echocardiography correlates well with left ventricular filling pressures in patients with heart failure. Cardiovasc Ultrasound. 2010;8:14.PubMedPubMedCentralCrossRefGoogle Scholar
  9. Campbell DJ, Mitchelhill KI, Schlicht SM, Booth RJ. Plasma amino-terminal pro-brain natriuretic peptide: a novel approach to the diagnosis of cardiac dysfunction. J Card Fail. 2000;6:130–9.PubMedCrossRefGoogle Scholar
  10. Cazzaniga M, Salerno F, Pagnozzi G, Dionigi E, Visentin S, Cirello I, Meregaglia D, Nicolini A. Diastolic dysfunction is associated with poor survival in patients with cirrhosis with transjugular intrahepatic portosystemic shunt. Gut. 2007;56:869–75.PubMedPubMedCentralCrossRefGoogle Scholar
  11. Dowsley TF, Bayne DB, Langnas AN, Dumitru I, Windle JR, Porter TR, Raichlin E. Diastolic dysfunction in patients with end-stage liver disease is associated with development of heart failure early after liver transplantation. Transplantation. 2012;94(6):646–51.PubMedCrossRefGoogle Scholar
  12. Fouad TR, Abdel-Razek WM, Burak KW, Bain VG, Lee SS. Prediction of cardiac complications after liver transplantation. Transplantation. 2009;87:763–70.PubMedCrossRefGoogle Scholar
  13. Garcia-Estan J, Ortiz MC, Lee SS. Nitric oxide and renal and cardiac dysfunction in cirrhosis. Clin Sci. 2002;102:213–22.PubMedCrossRefGoogle Scholar
  14. Henriksen JH, Fuglsang S, Bendtsen F, Christensen E, Møller S. Dyssynchronous electrical and mechanical systole in patients with cirrhosis. J Hepatol. 2002;36:513–20.PubMedCrossRefGoogle Scholar
  15. Henriksen JH, Gotze JP, Fuglsang S, Christensen E, Bendtsen F, Moller S. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut. 2003;52:1511–7.PubMedPubMedCentralCrossRefGoogle Scholar
  16. Hoyert D, Xu J. Deaths: preliminary data for 2011. Natl Vital Stat Rep. 2012;61:1–51.PubMedGoogle Scholar
  17. Kazankov K, Holland-Fischer P, Andersen NH, Torp P, Sloth E, Aagaard NK, Vilstrup H. Resting myocardial dysfunction in cirrhosis quantified by tissue Doppler imaging. Liver Int. 2011;31:534–40.PubMedCrossRefGoogle Scholar
  18. Kowalski HJ, Abelmann WH. The cardiac output at rest in Laennec’s cirrhosis. J Clin Invest. 1953;32:1025–33.PubMedPubMedCentralCrossRefGoogle Scholar
  19. Krag A, Bendtsen F, Mortensen C, Henriksen JH, Møller S. Effects of a single terlipressin administration on cardiac function and perfusion in cirrhosis. Eur J Gastroenterol Hepatol. 2010;22:1085–92.PubMedCrossRefGoogle Scholar
  20. Lee SS, Liu H. Cardiovascular determinants of survival in cirrhosis. Gut. 2007;56:746–8.PubMedPubMedCentralCrossRefGoogle Scholar
  21. Liu H, Gaskari SA, Lee SS. Cardiac and vascular changes in cirrhosis: pathogenic mechanisms. World J Gastroenterol. 2006;12:837–42.PubMedPubMedCentralCrossRefGoogle Scholar
  22. Lossnitzer D, Steen H, Zahn A, Lehrke S, Weiss C, Weiss KH, et al. Myocardial late gadolinium enhancement cardiovascular magnetic resonance in patients with cirrhosis. J Cardiovasc Magn Reson. 2010;12:47.PubMedPubMedCentralCrossRefGoogle Scholar
  23. Ma Z, Miyamoto A, Lee SS. Role of altered beta-adrenoceptor signal transduction in the pathogenesis of cirrhotic cardiomyopathy in rats. Gastroenterology. 1996;110:1191–8.PubMedCrossRefGoogle Scholar
  24. Madhwal S, Atreja A, Albeldawi M, Lopez R, Post A, Costa MA. Is liver transplantation a risk factor for cardiovascular disease? A meta-analysis of observational studies. Liver Transpl. 2012;18:1140–6.PubMedCrossRefGoogle Scholar
  25. McCaughan GW. Trekking new ground: overcoming medical and social impediments for extended criteria liver transplant recipients. Liver Transpl. 2012;18(Suppl 2):S39–46.PubMedCrossRefGoogle Scholar
  26. Møller S, Henriksen JH. Cirrhotic cardiomyopathy. J Hepatol. 2010;53:179–90.PubMedCrossRefGoogle Scholar
  27. Mor-Avi V, Lang RM, Badano LP, Belohlavek M, Cardim NM, Derumeaux G, et al. Current and evolving echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE/EAE consensus statement on methodology and indications endorsed by the Japanese Society of Echocardiography. Eur J Echocardiogr. 2011;12:167–205.PubMedCrossRefGoogle Scholar
  28. Murray JF, Dawson AM, Sherlock S. Circulatory changes in chronic liver disease. Am J Med. 1958;24:358–67.PubMedCrossRefGoogle Scholar
  29. Pozzi M, Grassi G, Ratti L, Favini G, Dell’Oro R, Redaelli E, et al. Cardiac, neuroadrenergic, and portal hemodynamic effects of prolonged aldosterone blockade in postviral child A cirrhosis. Am J Gastroenterol. 2005;100:1110–6.PubMedCrossRefGoogle Scholar
  30. Rudzinski W, Waller AH, Prasad A, Sood S, Gerula C, Samanta A, Koneru B, Klapholz M. New index for assessing the chronotropic response in patients with end-stage liver disease who are undergoing dobutamine stress echocardiography. Liver Transpl. 2012;18:355–60.PubMedCrossRefGoogle Scholar
  31. Ripoll C, Yotti R, Bermejo J, Bañares R. The heart in liver transplantation. J Hepatol. 2011;54:810–22.PubMedCrossRefGoogle Scholar
  32. Ruiz-del-Arbol L, Monescillo A, Arocena C, Valer P, Gines P, Moreira V, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology. 2005;42:439–47.PubMedCrossRefGoogle Scholar
  33. Sersté T, Francoz C, Durand F, Rautou PE, Melot C, Valla D, Moreau R, Lebrec D. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study. J Hepatol. 2011;55:794–9.PubMedCrossRefGoogle Scholar
  34. Therapondos G, Flapan AD, Dollinger MM, Garden OJ, Plevris JN, Hayes PC. Cardiac function after orthotopic liver transplantation and the effects of immunosuppression: a prospective randomized trial comparing cyclosporin (Neoral) and tacrolimus. Liver Transpl. 2002;8:690–700.PubMedCrossRefGoogle Scholar
  35. Torregrosa M, Aguadé S, Dos L, Segura R, Gónzalez A, Evangelista A, et al. Cardiac alterations in cirrhosis: reversibility after liver transplantation. J Hepatol. 2005;42:68–74.PubMedCrossRefGoogle Scholar
  36. Trevisani F, Di Micoli A, Zambruni A, Biselli M, Santi V, Erroi V, et al. QT interval prolongation by acute gastrointestinal bleeding in patients with cirrhosis. Liver Int. 2012;32:1510–5.PubMedCrossRefGoogle Scholar
  37. Williams K, Lewis JF, Davis G, Geiser EA. Dobutamine stress echocardiography in patients undergoing liver transplantation evaluation. Transplantation. 2000;69:2354–6.PubMedCrossRefGoogle Scholar
  38. Wong F, Girgrah N, Graba J, Allidina Y, Liu P, Blendis L. The cardiac response to exercise in cirrhosis. Gut. 2001;49:268–75.PubMedPubMedCentralCrossRefGoogle Scholar
  39. Wong F, Siu S, Liu P, Blendis LM. Brain natriuretic peptide: is it a predictor of cardiomyopathy in cirrhosis? Clin Sci. 2001;101:621–8.PubMedCrossRefGoogle Scholar
  40. Wong F. Cirrhotic cardiomyopathy. Hepatol Int. 2009;3:294–304.PubMedCrossRefGoogle Scholar
  41. Yang YY, Lin HC. The heart: pathophysiology and clinical implications of cirrhotic cardiomyopathy. J Chin Med Assoc. 2012;75:619–23.PubMedCrossRefGoogle Scholar
  42. Zardi EM, Abbate A, Zardi DM, Dobrina A, Margiotta D, Van Tassell BW, et al. Cirrhotic Cardiomyopathy. J Am Coll Cardiol. 2010;56:539–49.PubMedCrossRefGoogle Scholar
  43. Ziada D, Gaber R, Kotb N, Ghazy M, Nagy H. Predictive value of N-terminal pro B-type natriuretic peptide in tissue Doppler-diagnosed cirrhotic cardiomyopathy. Heart Mirror J. 2011;5:264–70.Google Scholar
  44. Zambruni A, Trevisani F, Di Micoli A, Savelli F, Berzigotti A, Bracci E. Effect of chronic beta-blockade on QT interval in patients with liver cirrhosis. J Hepatol. 2008;48:415–21.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Roxana Cristina Rimbas
    • 1
    • 2
  • Alexandra Maria Chitroceanu
    • 1
  • Dragos Vinereanu
    • 1
    • 2
  1. 1.University of Medicine and Pharmacy Carol DavilaBucharestRomania
  2. 2.Cardiology DepartmentUniversity and Emergency HospitalBucharestRomania

Personalised recommendations